Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor.

Mollica V, Di Nunno V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Jun 18. doi: 10.1097/CAD.0000000000000663. [Epub ahead of print]

PMID:
29916898
2.

Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer.

Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R.

Expert Rev Mol Diagn. 2018 Jun 29:1-11. doi: 10.1080/14737159.2018.1490179. [Epub ahead of print]

PMID:
29912582
3.

Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A.

Drugs Context. 2018 Jun 5;7:212528. doi: 10.7573/dic.212528. eCollection 2018.

4.

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.

Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Cortelezzi A.

J Hematol Oncol. 2018 Jun 11;11(1):79. doi: 10.1186/s13045-018-0626-0.

5.

Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies.

Massari F, Santoni M, di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, Battelli N, Montironi R.

Cancer Treat Rev. 2018 Jun 5;68:80-85. doi: 10.1016/j.ctrv.2018.06.002. [Epub ahead of print] Review.

PMID:
29886353
6.

Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ; Faculty for approval of the Consensus Document .

Eur Heart J Suppl. 2018 May;20(Suppl F):F1-F74. doi: 10.1093/eurheartj/suy019. Epub 2018 May 31.

7.

[ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].

Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, Scotto Di Uccio F, Urbinati S, Varbella F, Zito GB, De Luca L.

G Ital Cardiol (Rome). 2018 May;19(5):263-331. doi: 10.1714/2907.29280. Italian.

PMID:
29853716
8.

Tivozanib for the treatment of renal cell carcinoma.

Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, Battelli N.

Expert Opin Pharmacother. 2018 Jun;19(9):1021-1025. doi: 10.1080/14656566.2018.1480722. Epub 2018 May 31.

PMID:
29851529
9.

Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma.

Di Nunno V, Mollica V, Corcioni B, Fiorentino M, Nobili E, Schiavina R, Golfieri R, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2018 Aug;29(7):710-715. doi: 10.1097/CAD.0000000000000644.

PMID:
29846249
10.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246
11.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C.

Clin Genitourin Cancer. 2018 May 7. pii: S1558-7673(18)30151-4. doi: 10.1016/j.clgc.2018.04.007. [Epub ahead of print]

PMID:
29803346
12.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Apr 19. pii: S1558-7673(18)30084-3. doi: 10.1016/j.clgc.2018.03.014. [Epub ahead of print]

PMID:
29753637
13.

223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience.

Boni G, Mazzarri S, Cianci C, Galli L, Farnesi A, Borsatti E, Bortolus R, Fratino L, Gobitti C, Lamaj E, Ghedini P, Rizzini EL, Massari F, Dionisi V, Fanti S, Volterrani D, Monari F.

Tumori. 2018 Apr 1:300891618765571. doi: 10.1177/0300891618765571. [Epub ahead of print]

PMID:
29714668
15.

Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.

Montironi R, Cimadamore A, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M.

Expert Rev Anticancer Ther. 2018 Jul;18(7):685-693. doi: 10.1080/14737140.2018.1469406. Epub 2018 Apr 27.

PMID:
29699428
16.

Combined caudal-superficial-epigastric axial pattern flap and full-thickness buccal mucosa graft for single-stage preputial reconstruction in six dogs.

Massari F, Montinaro V, Buracco P, Romanelli G.

J Small Anim Pract. 2018 Jul;59(7):415-421. doi: 10.1111/jsap.12836. Epub 2018 Apr 17.

PMID:
29665060
17.
18.

Circulating tumor cells in genitourinary tumors.

Massari F, Di Nunno V, Comito F, Cubelli M, Ciccarese C, Iacovelli R, Fiorentino M, Montironi R, Ardizzoni A.

Ther Adv Urol. 2017 Nov 22;10(2):65-77. doi: 10.1177/1756287217742564. eCollection 2018 Feb. Review.

19.

Immune checkpoint inhibitors for metastatic bladder cancer.

Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A.

Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Review.

PMID:
29407369
20.

Atezolizumab for platinum-treated metastatic urothelial carcinoma.

Massari F, Di Nunno V.

Lancet. 2018 Feb 24;391(10122):716-718. doi: 10.1016/S0140-6736(17)33298-1. Epub 2017 Dec 18. No abstract available.

PMID:
29268949
21.

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G.

Oncotarget. 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21.

22.

Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

Ghedini P, Bossert I, Zanoni L, Ceci F, Graziani T, Castellucci P, Ambrosini V, Massari F, Nobili E, Melotti B, Musto A, Zoboli S, Antunovic L, Kirienko M, Chiti A, Mosconi C, Ardizzoni A, Golfieri R, Fanti S, Nanni C.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):751-758. doi: 10.1007/s00259-017-3888-9. Epub 2017 Nov 30.

PMID:
29192364
23.

Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.

Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R.

Mod Pathol. 2018 Jan;31(1):24-38. doi: 10.1038/modpathol.2017.104. Epub 2017 Nov 17. Review.

24.
25.

Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion.

Montironi R, Cimadamore A, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M.

Arch Pathol Lab Med. 2017 Nov;141(11):1460-1461. doi: 10.5858/arpa.2017-0198-LE. No abstract available.

PMID:
29072947
26.

Adjuvant therapy in renal cell carcinoma.

Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DYC.

Cancer Treat Rev. 2017 Nov;60:152-157. doi: 10.1016/j.ctrv.2017.09.004. Epub 2017 Sep 23. Review.

PMID:
28992528
27.

Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.

Zanchetta MB, Boailchuk J, Massari F, Silveira F, Bogado C, Zanchetta JR.

Osteoporos Int. 2018 Jan;29(1):41-47. doi: 10.1007/s00198-017-4242-6. Epub 2017 Oct 3.

PMID:
28975362
28.

Supraventricular tachycardia, pregnancy, and water: A new insight in lifesaving treatment of rhythm disorders.

Massari F, Scicchitano P, Potenza A, Sassara M, Sanasi M, Liccese M, Ciccone MM, Caldarola P.

Ann Noninvasive Electrocardiol. 2018 May;23(3):e12490. doi: 10.1111/anec.12490. Epub 2018 Apr 10.

PMID:
28833859
29.

Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians.

Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R.

Asian J Androl. 2017 Aug 4. doi: 10.4103/aja.aja_24_17. [Epub ahead of print]

30.

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.

Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G.

Eur J Cancer. 2017 Sep;83:237-246. doi: 10.1016/j.ejca.2017.06.030. Epub 2017 Jul 27. Review.

PMID:
28756136
31.

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK, Goemaere S, Hyldstrup L, Jodar-Gimeno E, Keaveny TM, Kendler D, Lakatos P, Maddox J, Malouf J, Massari FE, Molina JF, Ulla MR, Grauer A.

Lancet. 2017 Sep 30;390(10102):1585-1594. doi: 10.1016/S0140-6736(17)31613-6. Epub 2017 Jul 26.

PMID:
28755782
32.

The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome.

Massari F, Ciccarese C, Hes O, Michal M, Caliò A, Fiorentino M, Giunchi F, D'Amuri A, Sanguedolce F, Sabbatini R, Guida A, Ardizzoni A, Porta C, Iacovelli R, Tortora G, Cima L, Ortega C, Lapini A, Martignoni G, Brunelli M.

Pathol Oncol Res. 2018 Jul;24(3):447-456. doi: 10.1007/s12253-017-0271-x. Epub 2017 Jul 10. Review.

PMID:
28695322
33.

[Management of outpatients with cardiac disease: follow-up timing and modalities].

Rossini R, Lina D, Ferlini M, Belotti G, Caico SI, Caravati F, Faggiano P, Iorio A, Lauri D, Lettieri C, Locati ET, Maggi A, Massari F, Mortara A, Moschini L, Musumeci G, Nassiacos D, Negri F, Pecora D, Pierini S, Pedretti R, Ravizza P, Romano M, Oliva F.

G Ital Cardiol (Rome). 2017 Jun;18(6):467-484. doi: 10.1714/2700.27608. Review. Italian.

PMID:
28631761
34.

Pathology and molecular updates in tumors of the prostate: towards a personalized approach.

Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R.

Expert Rev Mol Diagn. 2017 Aug;17(8):781-789. doi: 10.1080/14737159.2017.1341314. Epub 2017 Jun 15. Review.

PMID:
28598696
35.

The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.

Ciccarese C, Iacovelli R, Bria E, Modena A, Massari F, Brunelli M, Fantinel E, Bimbatti D, Zamboni GA, Artibani W, Tortora G.

Immunotherapy. 2017 Jun;9(7):579-587. doi: 10.2217/imt-2017-0018.

PMID:
28595514
36.

Future perspectives for personalized immunotherapy in renal cell carcinoma.

Ciccarese C, Di Nunno V, Iacovelli R, Massari F.

Expert Opin Biol Ther. 2017 Sep;17(9):1049-1052. doi: 10.1080/14712598.2017.1339030. Epub 2017 Jun 7. No abstract available.

PMID:
28592155
37.

Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790-807.

Montironi R, Gasparrini S, Lopez-Beltran A, Cheng L, Massari F, Montorsi F, Scarpelli M.

Eur Urol. 2017 Nov;72(5):e139-e141. doi: 10.1016/j.eururo.2017.05.029. Epub 2017 May 31. No abstract available.

PMID:
28576502
38.

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G.

Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

PMID:
28572027
39.

Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?

Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F.

Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549.

PMID:
28524006
40.

Urinary Biomarkers for Prostate Cancer.

Giunchi F, Ciccarese C, Montironi R, Scarpelli M, Lopez-Beltran A, Cheng L, Moch H, Massari F, Fiorentino M.

Curr Drug Metab. 2017 Oct 16;18(8):723-726. doi: 10.2174/1389200218666170518161140.

PMID:
28524004
41.

Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.

Mann SA, Lopez-Beltran A, Massari F, Pili R, Fiorentino M, Koch MO, Kaimakliotis HZ, Wang L, Scarpelli M, Ciccarese C, Moch H, Montironi R, Cheng L.

Curr Drug Metab. 2017 Oct 16;18(8):700-711. doi: 10.2174/1389200218666170518162500.

PMID:
28524003
42.

Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice.

Blanca A, Cheng L, Montironi R, Moch H, Massari F, Fiorentino M, Raspollini MR, Scarpelli M, Lopez-Beltran A.

Curr Drug Metab. 2017 Oct 16;18(8):712-722. doi: 10.2174/1389200218666170518164507.

PMID:
28524002
43.

Pipeline Embolization Device for Pericallosal Artery Aneurysms: A Retrospective Single Center Safety and Efficacy Study.

De Macedo Rodrigues K, Kühn AL, Tamura T, Dabus G, Kan P, Marosfoi MG, Lozano JD, Perras M, Brooks C, Howk MC, Hou SY, Rex DE, Massari F, Gounis MJ, Wakhloo AK, Puri AS.

Oper Neurosurg (Hagerstown). 2018 Apr 1;14(4):351-358. doi: 10.1093/ons/opx111.

PMID:
28521024
44.

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S.

Tumori. 2017 Sep 18;103(5):405-421. doi: 10.5301/tj.5000625. Epub 2017 May 10. Review.

PMID:
28497847
45.

Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Lolli C, Aieta M, Scarpi E, Bianchi E, Maines F, Schepisi G, Salvi S, Massari F, Carrozza F, Veccia A, Chiuri VE, Campadelli E, Facchini G, De Giorgi U.

Prostate. 2017 Jun;77(9):1012-1019. doi: 10.1002/pros.23357. Epub 2017 Apr 20.

PMID:
28429372
46.

[The slow acceptance of new oral anticoagulants in Italy: a critical analysis of a problem].

Botto GL, Cuccia C, Gronda E, Lombardi F, Lunati M, Maggi A, Massari FM, Musumeci G, Oliva F, Visconti LO, Proto C, Pusineri E, Ageno W.

G Ital Cardiol (Rome). 2017 Mar;18(3):208-218. doi: 10.1714/2674.27398. Review. Italian.

PMID:
28398379
47.

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R.

Cancer Treat Rev. 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9. Review.

PMID:
28340451
49.

Tp53 and its potential therapeutic role as a target in bladder cancer.

Ciccarese C, Massari F, Blanca A, Tortora G, Montironi R, Cheng L, Scarpelli M, Raspollini MR, Vau N, Fonseca J, Lopez-Beltran A.

Expert Opin Ther Targets. 2017 Apr;21(4):401-414. doi: 10.1080/14728222.2017.1297798. Epub 2017 Mar 1. Review.

PMID:
28281901
50.

Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.

Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G.

Cancer Treat Rev. 2017 Mar;54:68-73. doi: 10.1016/j.ctrv.2017.02.001. Epub 2017 Feb 11. Review.

PMID:
28231559

Supplemental Content

Loading ...
Support Center